For a stock that had been struggling for significance for much of the past year, this dramatic shift was not merely a rally — ...

Through the first three quarters of 2025, M&A activity overtook the entire 2024 total, according to Endpoints News. Editor and founder John Carroll wrote in October this might be the best time in 15 ...

REGAL is a Phase 3 randomized study testing GPS in AML patients who reached complete remission after a second round of rescue ...

The Portfolio returned 7.33% gross, significantly outperforming the MSCI World Health Care Index's 3.12% return. Click here ...

The average one-year price target for Wave Life Sciences (NasdaqGM:WVE) has been revised to $32.70 / share. This is an increase of 60.82% from the prior estimate of $20.34 dated December 3, 2025. The ...

Salesforce (NYSE: CRM), the world’s #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global innovative ...

Life Sciences ventures face high levels of scientific, clinical and commercial pathway uncertainty, and these uncertainties present many opportunities for entrepreneurial innovation. This course is ...

The 2024-25 Sustainability Report reflects the company’s long-term view-one that places science, responsibility, and ...

The developer behind Philadelphia's largest life sciences building says the market needs patience after venture capital ...

Understand the fundamentals that drive life. Do basic research that leads to medical breakthroughs and improvements in our world. Study the underlying chemistry of organisms and ecosystems. Help ...

The Board on Life Sciences (BLS) was established in 1984 to serve as the focal point for addressing critical, emerging policy and technical issues associated with the life sciences and biotechnology ...